symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
PRLD,2.57,0.397361,108775,140858359,0,2.36-8.665,0.12,Prelude Therapeutics Incorporated,USD,0001678660,US74065P1012,74065P101,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.preludetx.com,"Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.","Dr. Krishna  Vaddi D.V.M., Ph.D.",Healthcare,US,122,302 467 1280,200 Powder Mill Road,Wilmington,DE,19803,,0,https://financialmodelingprep.com/image-stock/PRLD.png,2020-09-25,False,False,True,False,False
